A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Purpose

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the U.S. substudy is to evaluate how well it works in the body (pharmacodynamic [PD]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.

Condition

  • Myasthenia Gravis

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of myasthenia gravis (MG) with generalized muscle weakness meeting the clinical criteria for generalized myasthenia gravis (gMG) as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II a/b, III a/b, or IVa/b at screening - Myasthenia Gravis - Activities of Daily Living (MG-ADL) score of greater than or equal to (>=) 6 at screening and baseline - Has sufficient venous access to allow drug administration by infusion and blood sampling as per the protocol - A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine pregnancy test at Day 1 prior to administration of study intervention - A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 days after receiving the last administration of study intervention - For the SC Substudy (Cohort 1): Has reasonable abdominal skin area for SC administration - For the SC Substudy (Cohort 1): Participants must be willing to comply with maintaining their stable dose of corticosteroids and/or immunosuppressants for the initial 8 weeks of the SC substudy, that is, through the SC Week 8 visit

Exclusion Criteria

  • Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her gMG, or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant - Has MGFA Class I disease or presence of MG crisis (MGFA Class V) at screening, history of MG crisis within 1 month of screening, or fixed weakness (and/or 'burnt out' MG) - Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the study - Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients - Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening - For the SC Substudy (Cohort 1): Participants who have undergone a recent tapering of their concomitant MG medication in the OLE - For the SC Substudy (Cohort 1): Participants actively deteriorating at the SC Dose 1 visit for the SC substudy such that they meet the criteria for Clinical Deterioration

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Nipocalimab 		Double-blind Placebo-controlled Phase: Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase. Open-label Extension (OLE) Phase: Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion till study end.
  • Drug: Nipocalimab
    Nipocalimab will be administered as an IV infusion.
    Other names:
    • JNJ-80202135, M281
  • Drug: Nipocalimab SC-LIV
    Nipocalimab will be administered subcutaneously.
Placebo Comparator
Placebo 		Double-blind Placebo-controlled Phase: Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.
  • Drug: Placebo
    Matching placebo will be administered as an IV infusion.
Experimental
Nipocalimab Subcutaneous (SC) 		OLE Phase: Participants from Cohort 1 will receive nipocalimab subcutaneous liquid in vial (SC-LIV) qw until Week 8. Participants with gMG from Cohort 2 who have not received nipocalimab previously, will receive nipocalimab SC-LIV until Week 8. Participants who complete the 8-week treatment period will have the opportunity to continue receiving nipocalimab SC-LIV qw in the Long term extension (LTE) period.
  • Drug: Nipocalimab SC-LIV
    Nipocalimab will be administered subcutaneously.

More Details

Status
Active, not recruiting
Sponsor
Janssen Research & Development, LLC

Study Contact